top of page


Gene Tox Lab Solutions is very excited about the upcoming release of a new and innovative genetic test. This is a cardiovascular-focused genetic report through the Illumina Global Screening Array platform. The new clinical report, “Gene Tox Cardiac Care”, is now being added to the company’s established clinical portfolio, that emphasizes medically actionable panels generated from genomic data to enable proactive approach to preventive health and risk management and to provide evidence-based guidance to both patients and healthcare providers on cardiovascular conditions.
With an estimate of 610,000 deaths every year, heart disease is one of the leading causes of death in the United States. Cardiovascular-related deaths are present not only in the high-risk population, where comorbidity with diabetes and obesity are frequently observed, but also in high performing athletes. In addition, many heart conditions, however, have few symptoms, are known to run in family, or result from a combination of different genetic and environmental causes, which might require changes in the patient’s care and lifestyle. As such, our lab prioritizes the clinical actionability of the Cardiac Care report to help physicians and patients understand the effect of the genetic components of these diseases in order to promote quality of care and employ effective preventive measures.
The new Cardiac Care report will feature over 110 genes from clinical databases spanning across more than 30 different cardiovascular conditions, ranging from cardiomyopathies to rare forms of long QT syndromes such as Andersen-Tawil and Jervell-Lange Nielsen syndromes. The report’s comprehensiveness also addresses hypercholesterolemia, atrial fibrillation, and aneurysms. The report will also include valuable insights on the conditions’ inheritance mode and zygosity to enable the relative follow-up testing and family planning.
The release date is anticipated by the end of March, 2020.

Image by Robina Weermeijer
bottom of page